148 related articles for article (PubMed ID: 28833354)
21. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
Kiesewetter B; Neuper O; Mayerhoefer ME; Dolak W; Lukas J; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2018 Feb; 36(1):49-55. PubMed ID: 28695630
[TBL] [Abstract][Full Text] [Related]
22. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma.
Ikeda JI; Kohara M; Tsuruta Y; Nojima S; Tahara S; Ohshima K; Kurashige M; Wada N; Morii E
Hum Pathol; 2017 Jan; 59():70-79. PubMed ID: 27666766
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
25. Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features.
Inagaki H; Chan JK; Ng JW; Okabe M; Yoshino T; Okamoto M; Ogawa H; Matsushita H; Yokose T; Matsuno Y; Nakamura N; Nagasaka T; Ueda R; Eimoto T; Nakamura S
Am J Pathol; 2002 Apr; 160(4):1435-43. PubMed ID: 11943727
[TBL] [Abstract][Full Text] [Related]
26. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
27. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
28. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
29. Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens.
Kojima M; Nakamura N; Shimizu K; Tamaki Y; Itoh H; Nakamura S
Int J Surg Pathol; 2008 Apr; 16(2):164-70. PubMed ID: 18417673
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the clinical characteristics and prognostic factors of gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.
Xu X; Wang Z; Yu Y; Wang Y; Zhang L; Sun B; Da W; Zhang Y
J Gastroenterol Hepatol; 2014 Sep; 29(9):1678-84. PubMed ID: 24730769
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME; Raderer M
Hematol Oncol; 2017 Jun; 35(2):177-186. PubMed ID: 26580149
[TBL] [Abstract][Full Text] [Related]
32. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience.
Raderer M; Wöhrer S; Streubel B; Troch M; Turetschek K; Jäger U; Skrabs C; Gaiger A; Drach J; Puespoek A; Formanek M; Hoffmann M; Hauff W; Chott A
J Clin Oncol; 2006 Jul; 24(19):3136-41. PubMed ID: 16769982
[TBL] [Abstract][Full Text] [Related]
33. Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Troch M; Zielinski C; Raderer M
Ann Oncol; 2009 Aug; 20(8):1446-7. PubMed ID: 19654203
[No Abstract] [Full Text] [Related]
34. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
Kiesewetter B; Raderer M
Hematol Oncol; 2020 Oct; 38(4):417-424. PubMed ID: 32469432
[TBL] [Abstract][Full Text] [Related]
36. Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection.
Akamatsu T; Mochizuki T; Okiyama Y; Matsumoto A; Miyabayashi H; Ota H
Helicobacter; 2006 Apr; 11(2):86-95. PubMed ID: 16579838
[TBL] [Abstract][Full Text] [Related]
37. Significance of CXCR3 expression in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication.
Yamamoto H; Nakamura T; Matsuo K; Tajika M; Kawai H; Ohmiya N; Niwa Y; Goto H; Nakamura S
Cancer Sci; 2008 Sep; 99(9):1769-73. PubMed ID: 18616679
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Kiesewetter B; Willenbacher E; Willenbacher W; Egle A; Neumeister P; Voskova D; Mayerhoefer ME; Simonitsch-Klupp I; Melchardt T; Greil R; Raderer M;
Blood; 2017 Jan; 129(3):383-385. PubMed ID: 27879257
[No Abstract] [Full Text] [Related]
39. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
Desai M; Newberry KJ; Romaguera J; Zhang L; Ou Z; Wang M
J Hematol Oncol; 2013 Aug; 6():55. PubMed ID: 23915913
[TBL] [Abstract][Full Text] [Related]
40. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.
Kuo SH; Chen LT; Wu MS; Kuo KT; Yeh KH; Doong SL; Yeh PY; Hsu HC; Tzeng YS; Lin CW; Lin JT; Cheng AL
J Pathol; 2007 Feb; 211(3):296-304. PubMed ID: 17167822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
